The successful clinical application of dual antigen targeting in hematologic malignancies like B-ALL (e.g., CD19 and CD22) has illustrated the feasibility of such an approach in solid tumors and is currently being investigated clinically in glioblastoma by co-targeting EGFR and IL13Rα2 (10–12). This evidence concerns the gene EGFR and glioblastoma.